- January 8, 2014
I often hear investors complain about the difficulty finding undiscovered and undervalued biotech stocks. With the year we've just had, many companies with compelling drugs in development also have valuations bid up, but hidden gems remain to be discovered in 2014.
- December 20, 2013
Editors of the journal Science ranked cancer immunotherapy at the top of their list of scientific achievements this past year:
"This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark."
- December 4, 2013
Les fonds américains convoitent les pépites de la biotechnologie française
Au cours des dix derniers jours de novembre, l'action d'Innate Pharma a progressé de 75 %. Cet engouement, la société de biotechnologie française, située à Marseille et spécialisée dans l'immuno-oncologie – une approche innovante pour traiter les cancers en dopant le système immunitaire –, le doit aux bonnes fées américaines qui se sont penchées sur son berceau.
- December 2, 2013
- November 27, 2013
Jérôme Tiollier, Executive Vice President and Chief Development Officer, was at the Agora of Presidents on ACTIONARIA (November 22, 2013, Paris, France)
- November 23, 2013
Innate financing confirms importance of US to European biotechs
Innate Pharma this week became the latest European drug developer to turn to the US to seek investor support. The French immuno-oncology company raised €20.3m ($27.3m) in a private placement directed exclusively at investors across the Atlantic, sending its Paris-listed shares to a six-year high.
- November 21, 2013
Le 21 novembre, la levée de fonds de 20 millions d'euros d'Innate Pharma aux USA a été le sujet abordé par Hervé Brailly, Président du Directoire d'Innate Pharma interviewé par Sébastien Couasnon, dans Intégrale Bourse, sur BFM Business.
- October 28, 2013
- October 17, 2013
On October 15, 2013, Innate Pharma (IPH.PA) presented a new proprietary technology for generating antibody-drug conjugates (ADCs) at the World ADC Summit in San Francisco.
The technology represents an opportunity for Innate to expand its portfolio of developmental candidatesor form strategic partnerships with leading companies.
- September 30, 2013
With very promising clinical results in oncology, immunotherapy is back at the front of the international scene. In France projects come out on the academic and industrial side.
In France several companies of biotechnology are already positioned in immunotherapy with, at the head, Transgene and Innate Pharma, whose results of products under development are expected impatiently
Article Monthly Pharmaceutiques September 2013 - Anne Pezet